Search results for " San"

showing 10 items of 3080 documents

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in pati…

2012

Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled…

AdultMalePediatricsmedicine.medical_specialtyAdolescentBlood Loss SurgicalSevere diseaseHemorrhageSettore MED/15 - Malattie Del SangueYoung AdultVon Willebrand factorCost of Illnesshemic and lymphatic diseaseshemophiliavon Willebrand FactorVon Willebrand diseasemedicineHumansIn patientProspective StudiesDesmopressinAdverse effectChildGenetics (clinical)AgedFactor VIIIbiologybusiness.industryDrug SubstitutionAnticoagulantsHematologyGeneral MedicineMiddle Agedmedicine.diseaseResponse to treatmentHospitalizationvon Willebrand DiseasesItalyChild Preschoolbiology.proteinPasteurizationObservational studyFemalebusinessmedicine.drug
researchProduct

Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer

2008

Limited information exists on the incidence of symptomatic venous thromboembolism (vTE) in patients undergoing chest surgery for lung cancer. Several factors increase the thromboembolic risk in patients undergoing surgery for lung cancer: the intrinsic procoagulant effect of cancer,extensive surgical intervention, dependent limb position in the operating room, and vessel injury consequent to the operation. Furthermore,these patients might be especially vulnerable to pulmonary embolism (PE) because of the loss of lung tissue and the presence of chronic obstructive pulmonary disease and cardiovascular diseases caused by smoking.t Older studies found a very high incidence of thromboembolic eve…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentSeverity of Illness Indexvenous thromboembolism thoracotomySettore MED/15 - Malattie Del SangueCohort StudiesAge DistributionPostoperative ComplicationsRisk FactorsmedicineHumansMulticenter Studies as TopicThoracotomySex DistributionLung cancerPneumonectomyAgedNeoplasm StagingRetrospective StudiesAged 80 and overOntariobusiness.industryVascular diseaseIncidence (epidemiology)IncidenceRespiratory diseaseCancerAnticoagulantsRetrospective cohort studyVenous ThromboembolismMiddle Agedmedicine.diseasePrognosisSurvival AnalysisSurgeryVenous thrombosisItalyThoracotomyFemaleSurgerybusinessPulmonary EmbolismCardiology and Cardiovascular MedicineThe Journal of Thoracic and Cardiovascular Surgery
researchProduct

Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.

2008

Objective Subtherapeutic international normalized ratios are frequently encountered in clinical practice, and patients with mechanical heart valves with inadequate anticoagulation may be exposed to an increased risk of thromboembolic events. There are no data on thromboembolic event risk for these patients. Methods We assessed the current practice patterns in the management of patients with mechanical heart valves with subtherapeutic international normalized ratios and assessed the risk of thromboembolic complications in this setting. The charts of patients with mechanical heart valves followed up in two anticoagulation clinics were reviewed. Patients with a history of stable, therapeutic a…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classLow molecular weight heparinProsthesis DesignRisk AssessmentSettore MED/15 - Malattie Del SangueCohort StudiesYoung AdultThromboembolismAntithromboticmedicineHumansInternational Normalized RatioINR anticoagulant mechanical heart valvesAgedRetrospective Studiesbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyMiddle AgedVitamin K antagonistConfidence intervalSurgeryHeart Valve ProsthesisFemaleSurgeryRisk assessmentbusinessCardiology and Cardiovascular MedicineCohort study
researchProduct

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

2011

We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfavorable (-7/7q-) prognosis and also show that other sole or two abnormalities that do not include i(17q), -5/5q-, 12p-, inv(3) or 11q23 rearrangement are prognostically aligned with normal karyotype, which is prognostically favorable. These findings were incorporated into a refined two-tired cytogenetic-risk stratification: unfavorable and favorable karyotype. The respective 5-y…

AdultMaleRiskCancer Researchmedicine.medical_specialtyPathologyAdolescentChromosomal translocationmyelofibrosisGastroenterologycytogeneticsDisease-Free SurvivalSettore MED/15 - Malattie Del SangueInternal medicineComplex KaryotypemedicineHumansMyelofibrosisAgedAged 80 and overChromosome AberrationsLeukemiaHematologyPlatelet Countbusiness.industryHazard ratioKaryotypeHematologyMiddle AgedPrognosismedicine.diseaseConfidence intervalkaryotypeOncologyPrimary MyelofibrosisInternational Prognostic Scoring SystemKaryotypingOriginal ArticleFemalemyeloproliferativebusiness
researchProduct

Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study.

2009

summaryKnowledge on the natural history of mesenteric vein thrombosis (MVT) and of the efficacy and safety of long-term oral anticoagulant therapy (OAT) in this setting is based on small uncontrolled series of patients with a limited follow-up. It was the aim of the study to assess the natural history of MVT in a cohort of patients treated with OAT. The charts of all MVT patients currently attending or who have attended four anticoagulation clinics were reviewed. Information on risk factors, treatment, recurrence, major bleeding and mortality was collected. Seventyseven patients (mean age 49.2 years; 45 males) were included with a median follow-up of 36 months (range 2–204 months). Forty-si…

AdultMaleRiskmedicine.medical_specialtyVitamin Kmedicine.drug_classmedicine.medical_treatmentSettore MED/15 - Malattie Del SangueCohort StudiesRisk FactorsmedicineHumansVeinAgedRetrospective StudiesAged 80 and overVenous ThrombosisChemotherapybusiness.industryAnticoagulantAnticoagulantsRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurgeryMesenteric ArteriesNatural historyVenous thrombosismedicine.anatomical_structuremesenteric vein thrombosisCohortFemalebusinessCohort study
researchProduct

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…

2012

No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…

AdultMaleRiskmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLow molecular weight heparinAntineoplastic AgentsHemorrhagelow-molecular weight heparin (LMWH); long-term vitamin-K antagonist (VKA) therapy; cancer patientsSettore MED/15 - Malattie Del SanguePostoperative ComplicationsNeoplasmsThromboembolismAtrial FibrillationHumansThrombophiliaMedicinecancer thrombocytopenia low molecular weight heparinProspective StudiesProspective cohort studyAgedAged 80 and overChemotherapybusiness.industryIncidenceWarfarinAnticoagulantsCancerHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaThrombosisSurgeryClinical trialHeart Valve ProsthesisAnesthesialow-molecular weight heparin (LMWH)FemaleWarfarinlong-term vitamin-K antagonist (VKA) therapycancer patientsbusinessmedicine.drugAmerican Journal of Hematology
researchProduct

Methodological considerations to determine the effect of exercise on brain-derived neurotrophic factor levels.

2015

Objectives: Physical exercise up-regulates brain-derived neurotrophic factor (BDNF) in the brain and blood. However, there is yet no consensus about the adequate blood processing conditions to standardize its assessment. We aimed to find a reliable blood sample processing method to determine changes in BDNF due to exercise. Design and methods: Twelve healthy university students performed an incremental cycling test to exhaustion. At baseline, immediately after exercise, and 30 and 60 min of recovery, venous blood was drawn and processed under different conditions, i.e. whole blood, serum coagulated for 10 min and 24 h, total plasma, and platelet-free plasma. BDNF concentration was measured …

AdultMaleSerummedicine.medical_specialtyHemoconcentrationClinical BiochemistryPhysical exerciseHemoconcentraciónPlasmaEnzyme-linked immunosorbent assayNeurotrophic factorsInternal medicinePlasma sanguineoSurveys and QuestionnairesMedicineHumansPlateletEducación físicaExerciseWhole bloodBrain-derived neurotrophic factorBlood Specimen Collectionbusiness.industryBrain-Derived Neurotrophic FactorGeneral MedicineVenous bloodHemoconcentrationWhole bloodEndocrinologyHomogeneousbusinessEnergy MetabolismClinical biochemistry
researchProduct

[Mediterranean spotted fever in paediatric and adult patients: two clinical aspects of the same disease].

2012

Mediterranean Spotted Fever is an acute febrile disease caused by Rickettsia conorii and transmitted to humans by the brown dog tick Rhipicephalus sanguineus. Nearly 400 cases are reported every year in Sicily, mainly from June to September. The aim of this study is to compare the clinical and laboratory features of two different groups of patients , one of adults and one of children. The analysis included all adult patients with MSF diagnosed at the Institute of Infectious Diseases, Paolo Giaccone University Polyclinic in Palermo, during the period January 2007- August 2010 and all the children diagnosed with MSF at the G. Di Cristina Children Hospital in Palermo during the period January …

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/17 - Malattie InfettiveAdolescentRhipicephalus sanguineusBoutonneuse FeverPolymerase Chain ReactionDogsAnimalsHumansChildFluorescent Antibody Technique IndirectSicilyAgedRetrospective StudiesMediterranean spotted fever Rickettsia paediatricadultIncidenceInfant NewbornInfantMiddle AgedAnti-Bacterial AgentsRickettsia conoriiTreatment OutcomeChild PreschoolArachnid VectorsFemaleLe infezioni in medicina
researchProduct

Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study.

2012

Summary.  Background:  Little information is available on the long-term clinical outcome of cerebral vein thrombosis (CVT). Objectives and methods:  In an international, retrospective cohort study, we assessed the long-term rates of mortality, residual disability and recurrent venous thromboembolism (VTE) in a cohort of patients with a first CVT episode. Results:  Seven hundred and six patients (73.7% females) with CVT were included. Patients were followed for a total of 3171 patient-years. Median follow-up was 40 months (range 6, 297 months). At the end of follow-up, 20 patients had died (2.8%). The outcome was generally good: 89.1% of patients had a complete recovery (modified Rankin Scor…

AdultMalemedicine.medical_specialtyAnticoagulant treatment; Cerebral vein thrombosis; Mortality; Recurrence; Adult; Cerebral Veins; Cohort Studies; Female; Humans; Male; Middle Aged; Recurrence; ThrombosisCohort StudiesAnticoagulant treatment; Cerebral vein thrombosis; Mortality; RecurrenceRecurrenceInternal medicinemedicineRisk of mortalityHumansMED/41 - ANESTESIOLOGIAMortalitybusiness.industryIncidence (epidemiology)Cerebral Vein thrombosiHazard ratioCerebral VeinRetrospective cohort studyThrombosisHematologyMiddle Agedmedicine.diseaseThrombosisCerebral VeinsConfidence intervalSurgerycerebral vein thrombosisSettore MED/15 - MALATTIE DEL SANGUEThrombosiCohortFemaleAnticoagulant treatmentCohort StudiebusinessHumanCohort studyJournal of thrombosis and haemostasis : JTH
researchProduct

Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin.

2009

Introduction: We tested the efficacy and safety of fixed doses of Low-Molecular Weight Heparin (LMWH) in patients requiring interruption of Vitamin-k Antagonist (VKA) because of invasive procedures Methodology: Pre-operatively, patients discontinued VKA 5 +/- 1days; in those at low-risk for thrombosis, LMWH was given at a prophylactic dosage of 3.800 U.I. (nadroparin) or 4.000 U.I. (enoxaparin) anti-FXa once daily the night before the procedure. In patients at high-risk for thrombosis, LMWH was started early after VKA cessation and given at fixed sub-therapeutic doses (3.800 or 4.000 UI anti-FXa twice daily) until surgery. Post-operatively, LMWH was reinitiated 12 hours after procedure whil…

AdultMalemedicine.medical_specialtyBridging low molecular weight heparinTime FactorsVitamin Kmedicine.drug_classLow molecular weight heparinAdministration OralPostoperative HemorrhageRisk AssessmentDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRisk FactorsThromboembolismmedicineHumansProspective StudiesEnoxaparinProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)WarfarinAnticoagulantsNadroparinHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryLow Molecular Weight Heparin Fixed doses Chronic oral anticoagulation perioperative bridgingAnesthesiaSurgical Procedures OperativeNadroparinFeasibility StudiesFemaleWarfarinbusinessmedicine.drugFactor Xa Inhibitors
researchProduct